Literature DB >> 10941962

A multicenter long-term safety and efficacy trial of preterm formula supplemented with long-chain polyunsaturated fatty acids.

J Vanderhoof1, S Gross, T Hegyi.   

Abstract

BACKGROUND: The tissue accretion of long-chain polyunsaturated fatty acids is compromised in infants born prematurely. Human milk contains long-chain polyunsaturated fatty acids, but most preterm infant formulas do not. The long-term effects of preterm formula supplemented with arachidonic acid and docosahexaenoic acid, in proportions typical of those in human milk, were therefore investigated.
METHODS: In this double-blind, randomized study, 288 preterm infants received experimental formula (n = 77), unsupplemented (control) formula (n = 78), or human milk (n = 133) until 48 weeks postconceptional age (PCA). Term formula, without supplemental long-chain polyunsaturated fatty acids, was administered from 48 to 92 weeks PCA to formula-fed infants and to infants weaned from human milk. Anthropometric and fatty acid data were assessed by using analysis of variance.
RESULTS: At 92 weeks PCA, no statistically significant anthropometric measurement differences were found except for midarm circumference, which was smaller in human milk-fed infants than in those fed formula. Phospholipid concentrations were similar in the experimental and human milk-fed groups, and docosahexaenoic acid levels were significantly greater than in the control group. The types and incidences of adverse events were similar among the feeding groups.
CONCLUSIONS: The results of this study demonstrate the efficacy and long-term safety of preterm formula supplemented with long-chain polyunsaturated fatty acids.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10941962     DOI: 10.1097/00005176-200008000-00007

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  6 in total

1.  Docosahexaenoic and Arachidonic Acid Supplementation of Toddlers Born Preterm Does Not Affect Short-Term Growth or Adiposity.

Authors:  Taniqua T Ingol; Rui Li; Kelly M Boone; Joseph Rausch; Mark A Klebanoff; Abigail Norris Turner; Keith O Yeates; Mary Ann Nelin; Kelly W Sheppard; Sarah A Keim
Journal:  J Nutr       Date:  2019-12-01       Impact factor: 4.798

Review 2.  Polyunsaturated fatty acids and infant growth.

Authors:  A Lapillonne; S E Carlson
Journal:  Lipids       Date:  2001-09       Impact factor: 1.880

3.  Randomized trials with polyunsaturated fatty acid interventions in preterm and term infants: functional and clinical outcomes.

Authors:  R A Gibson; W Chen; M Makrides
Journal:  Lipids       Date:  2001-09       Impact factor: 1.880

Review 4.  Longchain polyunsaturated fatty acid supplementation in preterm infants.

Authors:  Kwi Moon; Shripada C Rao; Sven M Schulzke; Sanjay K Patole; Karen Simmer
Journal:  Cochrane Database Syst Rev       Date:  2016-12-20

Review 5.  Polyunsaturated fatty acid supplementation in infancy for the prevention of allergy.

Authors:  Tim Schindler; John Kh Sinn; David A Osborn
Journal:  Cochrane Database Syst Rev       Date:  2016-10-28

Review 6.  The Essentiality of Arachidonic Acid in Infant Development.

Authors:  Kevin B Hadley; Alan S Ryan; Stewart Forsyth; Sheila Gautier; Norman Salem
Journal:  Nutrients       Date:  2016-04-12       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.